New therapy
TREG therapy
innovative cell therapy
academic clinical trials
treatment of DM1
treatment of type
cell identification
regulatory pathways
regulatory requirements
sorting
innovative model
identification of new business models
scope of current regulatory landscape
project’s objective
project’s outcome
Commercialization of TREG cells
local government
state
national health funds
PolTREG
economy
society
proliferation
transport
culture
devastating disease
patient
possibility
banking
steps
macro-scale
payer
insurance
necessary strategy
strict quality control
delivery
multiplication
production of vaccines
commercial success
use of TREGs vaccine
Elaboration of feasibility study
effects
technology
pension scheme
patent
Company
basis of acceptance
diabetes
EMA
aspects